ADDERALL 30mg. Capsules.

$405.00$1,080.00

in stock
SKU: ADD-30

Product it’s in Stock and ready to go out, the Price include the release of the Prescription, Duty Free, Tax and all Fees, and We also send all orders from a Safe Place, to avoid Mail Lifters, Customs Hassle and Shipping Issues, and We always use Special Courier Companies like FedEx and/or U.P.S. Via Two Days Air and/or Second Day Air, with no signature required, and We do send discrete flat envelope with no Medical or Pharmaceutical Tags, to Protect the Right of Privacy of our Customers; We also have a Confidentiality Clause, and We don’t Share Information with Third Persons.

Clear

Description

FORMULATION:

Dextroamphetamine Saccharate   7.5mg.

Amphetamine Aspartate          7.5mg.

Dextroamphetamine Sulfate      7.5mg.

Amphetamine Sulfate            7.5mg.

 

BOXED WARNING

DOSAGE & INDICATIONS

Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction

Amphetamine; dextroamphetamine is contraindicated in patients with symptomatic cardiac disease, advanced arteriosclerosis, and moderate to severe hypertension. The FDA recommends that, in general, stimulant medications not be used in patients with known serious cardiac structural abnormalities, a history of acute myocardial infarction, aortic stenosis, prosthetic heart valves, valvular heart disease, cardiomyopathy, ventricular dysfunction or heart failure, cardiac arrhythmias, coronary artery disease, or other serious cardiac problems. Stimulant medications may increase blood pressure or heart rate in some individuals; more serious cardiac effects have also been associated with stimulant use. Sudden unexplained death (SUD) and myocardial infarction have occurred in adults receiving stimulants at standard dosages for attention-deficit hyperactivity-disorder (ADHD). Sudden death has also been associated with stimulant medications at usual doses in pediatrics with structural cardiac abnormalities or other serious heart problems. A large retrospective cohort study including over 1.2 million children and young adults 2—24 years of age did not find an increased risk of serious cardiovascular events in current users of drugs for the treatment of ADHD compared to nonusers (adjusted hazard ratio 0.75; 95% CI 0.31—1.85). Similar results were seen when current users of ADHD drugs were compared to former users and when current users with severe underlying cardiovascular disease were included in the analysis. The authors concluded that although the absolute magnitude of risk appears to be low, a modest increase in risk could not be ruled out. The American Heart Association (AHA) states that it is reasonable to consider the use of these medications in pediatric patients with congenital heart disease without current hemodynamic or arrhythmic concerns or congenital heart disease that is considered stable by the patient’s pediatric cardiologist, unless the cardiologist has specific concerns. However, these patients should be closely monitored and treatment discontinuation should be considered if the patient develops any of the following conditions: heart condition associated with sudden cardiac death (SCD), arrhythmia requiring cardiopulmonary resuscitation, direct current cardioversion/defibrillation or overdrive pacing, arrhythmia associated with SCD, any clinically significant arrhythmia that is not treated or controlled, QTc on electrocardiogram (ECG) > 0.46 sec, or heart rate or blood pressure > 2 SD above the mean for age. All patients being considered for treatment with stimulant medications should have a careful history taken, including assessment for a family history of sudden death or ventricular arrhythmias, and a physical exam to assess for the presence of cardiac disease. If cardiac disease is suspected, further cardiac evaluation including an ECG and echocardiogram is warranted. For pediatric patients, the AHA states that it is reasonable to obtain a baseline ECG as a part of the initial evaluation. If a child or adolescent has any significant findings on physical examination, ECG, or family history, consult a pediatric cardiologist before initiating the stimulant medication. Once the medication is started, a repeat ECG may be helpful if the original ECG was obtained before the child was 12 years old, if cardiac symptoms develop, or there is a change in family history.

DEA CLASS

Rx, schedule II

DESCRIPTION

Central nervous system (CNS) stimulant
Used for attention-deficit hyperactivity disorder (ADHD) and narcolepsy
Patients with structural heart defects, cardiomyopathy, or heart-rhythm disturbances may be at risk for adverse cardiac events

COMMON BRAND NAMES

Adderall, Adderall XR, Mydayis

HOW SUPPLIED

Adderall XR/Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate/Amphetamine, Dextroamphetamine/Mydayis Oral Cap ER: 5mg, 10mg, 15mg, 20mg, 25mg, 30mg
Adderall/Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate/Amphetamine, Dextroamphetamine Oral Tab: 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg, 30mg

DOSAGE & INDICATIONS

For the treatment of attention-deficit hyperactivity disorder (ADHD).
Oral dosage (immediate-release tablets; e.g., Adderall)
Adults

Initially, 5 mg PO once daily or twice daily. If divided doses are required, give first dose upon awakening and the subsequent doses (1 or 2) at 4 to 6 hour intervals. Titrate by no more than 5 mg/day at weekly intervals to the minimum effective dose; doses greater than 60 mg/day PO are not usually needed. Dosage should be individualized; use lowest effective dose after stabilization. Lack of response to one stimulant does not predict a response to other stimulants. ADHD is a chronic condition that requires ongoing management and monitoring. Treatment strategies must be individualized for patients based on psychosocial and comorbid factors. In treatment guidelines, stimulants are considered first-line therapy in the treatment of ADHD.

Children and Adolescents 6 years and older

5 mg PO once or twice daily. May titrate daily dose in 5 mg increments at weekly intervals to minimum effective dose. Daily dose may be given in 1 to 3 divided doses at 4 to 6 hour intervals. Although FDA-approved labeling states doses greater than 40 mg/day are rarely necessary, some experts recommend a max dose of 60 mg/day in patients weighing more than 50 kg. Dosage should be individualized; use lowest effective dose after stabilization. Lack of response to one stimulant does not predict a response to other stimulants. ADHD is a chronic condition that will require ongoing management and monitoring. Sixty to eighty percent of children will continue to need treatment in adulthood. Treatment strategies must be individualized for patients based on psychosocial and comorbid factors. In treatment guidelines, stimulants are considered first-line therapy in the treatment of ADHD.

Children 3 to 5 years

2.5 mg PO once daily in the morning. May titrate daily dose in 2.5 mg increments at weekly intervals to minimum effective dose. Daily dose may be given in 1 to 3 divided doses at 4 to 6 hour intervals. Maximum dosage information is not available; however, doses should not exceed 40 mg/day, the maximum recommended dose for children ages 6 to 12 years. Although this dosing information is available in the FDA-approved package labeling, the American Academy of Pediatrics (AAP) does not recommend the use of amphetamine; dextroamphetamine in this age group due to lack of safety and efficacy data.

Oral dosage (extended-release capsules; e.g., Adderall XR)
Adults

When initiating treatment for the first time or switching from another ADHD medication, the recommended dose is 20 mg PO once daily upon awakening. CONVERSION FROM ANOTHER DOSAGE FORM OF AMPHETAMINES SALTS: Adults taking divided doses of the immediate-release formulation may be switched to the extended-release (ER) formulation once daily at the same total daily dose. TITRATION: Adjust upward or downward at weekly intervals if needed; dose should be based on individual response and tolerability. During adult ADHD trials, there was not adequate evidence that doses greater than 20 mg/day ER capsules conferred additional benefit; during these trials, 60 mg PO once daily was the highest titration dose used. STABILIZATION: Dose should be based on individual response and tolerability; use lowest effective dose after stabilization. Lack of response to one stimulant does not predict a response to other stimulants. ADHD is a chronic condition that will require ongoing management and monitoring. Treatment strategies must be individualized for patients based on psychosocial and comorbid factors. In treatment guidelines, stimulants are considered first-line therapy in the treatment of ADHD.

Adolescents

10 mg PO once daily in the morning for both initial therapy and when converting to extended-release amphetamine; dextroamphetamine from another stimulant medication. May titrate to 20 mg PO once daily after 1 week if ADHD symptoms are not adequately controlled. CONVERSION FROM ANOTHER DOSAGE FORM OF AMPHETAMINES SALTS: Adolescents taking divided doses of the immediate-release formulation may be switched to the extended-release (ER) formulation once daily at the same total daily dose. TITRATION: Adjust upward or downward at weekly intervals if needed; dose should be based on individual response and tolerability. During clinical trials, there was not adequate evidence that doses greater than 20 mg/day conferred additional benefit in patients 13 to 17 years of age. In clinical trials, maximum titration doses were 40 mg/day PO ER capsules for patients weighing 75 kg or less and from 50 to 60 mg/day PO ER capsules for those weighing more than 75 kg. STABILIZATION: Dose should be based on individual response and tolerability; use lowest effective dose after stabilization. Lack of response to one stimulant does not predict a response to other stimulants. ADHD is a chronic condition that will require ongoing management and monitoring. Sixty to eighty percent of children will continue to need treatment in adulthood. Treatment strategies must be individualized for patients based on psychosocial and comorbid factors. In treatment guidelines, stimulants are considered first-line therapy in the treatment of ADHD.

Children 6 to 12 years

5 to 10 mg PO once daily in the morning for initial treatment. If converting to extended-release (ER) amphetamine; dextroamphetamine from a different stimulant medication, begin with 10 mg PO once daily. May titrate daily dose in 5 to 10 mg increments at weekly intervals to the minimum effective dose. Max: 30 mg/day PO ER capsules. CONVERSION FROM ANOTHER DOSAGE FORM OF AMPHETAMINES SALTS: Children taking divided doses of immediate-release amphetamine; dextroamphetamine may switch to the extended-release formulation PO once daily at the same total daily dose, not to exceed 30 mg/day PO for ER capsules. Dosage should be individualized; use lowest effective dose after stabilization. Lack of response to one stimulant does not predict a response to other stimulants. ADHD is a chronic condition that will require ongoing management and monitoring. Sixty to eighty percent of children will continue to need treatment in adulthood. Treatment strategies must be individualized for patients based on psychosocial and comorbid factors. In treatment guidelines, stimulants are considered first-line therapy in the treatment of ADHD.

Oral dosage (extended-release capsules; e.g., Mydayis)
Adults

Initially, 12.5 mg PO once daily in the morning upon awakening; take consistently with or without food. If a dose is missed, do not administer later in the day. Dose may be increased by 12.5 mg increments at weekly intervals. Max: 50 mg/day. Dosage should be individualized; use lowest effective dose after stabilization. For patients switching from another medication or any other amphetamine products, discontinue that treatment, and titrate using the titration schedule. Do not substitute for other amphetamine products on a milligram-per-milligram basis. Lack of response to one stimulant does not predict a response to other stimulants. ADHD is a chronic condition that requires ongoing management and monitoring. Treatment strategies must be individualized for patients based on psychosocial and comorbid factors. In treatment guidelines, stimulants are considered first-line therapy in the treatment of ADHD.

Adolescents 13 years and older

Initially, 12.5 mg PO once daily in the morning upon awakening; take consistently with or without food. If a dose is missed, do not administer later in the day. Dose may be increased by 12.5 mg increments at weekly intervals. Max: 25 mg/day. Dosage should be individualized; use lowest effective dose after stabilization. For patients switching from another medication or any other amphetamine products, discontinue that treatment, and titrate using the titration schedule. Do not substitute for other amphetamine products on a milligram-per-milligram basis. Lack of response to one stimulant does not predict a response to other stimulants. ADHD is a chronic condition that will require ongoing management and monitoring. Sixty to eighty percent of children will continue to need treatment in adulthood. Treatment strategies must be individualized for patients based on psychosocial and comorbid factors. In treatment guidelines, stimulants are considered first-line therapy in the treatment of ADHD.

For the treatment of narcolepsy.
Oral dosage (immediate-release tablets; e.g., Adderall)
Adults, Adolescents, and Children 12 years and older

Initially, 10 mg PO once daily in the morning. If divided doses are required, give first dose upon awakening and the subsequent doses (1 or 2) at 4 to 6 hour intervals. Titrate by no more than 10 mg/day at weekly intervals to the minimum effective dose. Maximum: 60 mg/day. Adjust dose requirements based on individual response. If bothersome adverse reactions appear (e.g., insomnia or anorexia), the dosage should be reduced.

Children 6 to 11 years

Initially, 5 mg PO once daily in the morning. May titrate daily dose in 5 mg increments at weekly intervals to minimum effective dose. Daily dose may be given in 1 to 3 divided doses at 4 to 6 hour intervals. If insomnia or anorexia appear, reduce dosage. Max: 60 mg/day.

For the short-term treatment (i.e., 3 to 6 weeks) of exogenous obesity† as an adjunct to dietary modification and exercise.
Oral dosage
Adults

The usual daily dosage range is 5 mg/day to 30 mg/day PO, administered as 5 mg/dose to 10 mg/dose 30 to 60 minutes before meals. Adjust based on individual response. For short-term (3 to 6 weeks) treatment only. NOTE: Therapy is considered only as an adjunct to diet and exercise; without these modifications weight gain resumes after drug discontinuation. Based on clinical trials, the anorectic effect is greater in the first few weeks of therapy and tends to decrease in subsequent weeks. The long-term effectiveness of these agents is limited.

†Indicates off-label use

MAXIMUM DOSAGE

Adults

60 mg/day PO for ADHD or narcolepsy for immediate-release tablets; 30 mg/day PO for obesity using immediate-release tablets. For extended-release Adderall XR capsules, 20 mg/day PO is the recommended dose; in clinical trials for adult ADHD, 60 mg/day PO was the highest titration dose used. 50 mg/day PO for ADHD using extended-release Mydayis capsules.

Geriatric

60 mg/day PO for ADHD or narcolepsy for immediate-release tablets; 30 mg/day PO for obesity using immediate-release tablets. For extended-release capsules, geriatric patients have not been specifically evaluated.

Adolescents

40 mg/day PO for ADHD or 60 mg/day PO for narcolepsy using immediate-release tablets; some experts recommend an off-label maximum of 60 mg/day PO if weight is greater than 50 kg for the treatment of ADHD. In clinical trials of extended-release Adderall XR capsules, titration doses were allowed up to 40 mg/day PO for weight 75 kg or less and from 50 to 60 mg/day PO for weight more than 75 kg; however, there was no consistent evidence that doses above 20 mg/day PO conferred additional benefit. 25 mg/day PO for ADHD using extended-release Mydayis capsules.

Children

6 years and older: 40 mg/day PO for ADHD or 60 mg/day PO for narcolepsy using immediate-release tablets; some experts recommend an off-label maximum of 60 mg/day PO if weight is more than 50 kg for the treatment of ADHD. Maximum 30 mg/day PO for ADHD using extended-release Adderall XR capsules.
3 to 5 years: Maximum dosage information is not provided by FDA-approved labeling; doses should not exceed 40 mg/day PO for immediate-release tablets. Do not use extended-release capsules.
Less than 3 years: Safety and efficacy have not been established.

Infants

Safety and efficacy have not been established.

DOSING CONSIDERATIONS

Hepatic Impairment

Specific guidelines for dosage adjustments in hepatic impairment are not available; the FDA-approved product labeling states that hepatic dysfunction has the potential to inhibit the elimination of amphetamine and result in prolonged exposures; use caution.

Renal Impairment

Specific guidelines for dosage adjustments of immediate-release tablets and extended-release capsules (Adderall XR) in renal impairment are not available; the FDA-approved product labeling states that renal dysfunction has the potential to inhibit the elimination of amphetamine and result in prolonged exposures; use caution.
eGFR 15 to 29 mL/minute/1.73 m2: Starting dose of extended-release capsules (Mydayis) is 12.5 mg daily with a maximum recommended dose of 25 mg/day (adults) and 12.5 mg/day (adolescents).
eGFR less than 15 mL/minute/1.73 m2: Initiation of extended-release capsules (Mydayis) is not recommended.

ADMINISTRATION

NOTE: A MedGuide is available which informs patients about the cardiac and psychiatric risks associated with use, and should be provided by the authorized dispenser to each patient receiving a prescription.

Oral Administration
Oral Solid Formulations

Immediate-release tablets: Administer the first dose of the day upon awakening. Subsequent doses during the day, if given, should be administered at least 6 hours before bedtime to avoid sleep interference.
Extended-release capsules (Adderall XR): Administer dose once daily upon awakening. Do not crush or chew the capsule or capsule contents (beads). If swallowing is difficult, the capsule may be opened and the entire contents gently sprinkled on a spoonful of cool applesauce and swallowed immediately (do not store for future use). Follow with a drink of water or other liquid.
Extended-release capsules (Mydayis): Administer dose once daily upon awakening consistently either with or without food. Do not crush or chew the capsule or capsule contents (beads). If swallowing is difficult, the capsule may be opened and the entire contents gently sprinkled on a spoonful of applesauce and swallowed immediately (do not store for future use). Do not divide the dose of a single capsule.

STORAGE

Adderall:
– Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Adderall XR:
– Store at controlled room temperature (between 68 and 77 degrees F)
Mydayis:
– Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F

Additional information

months

, ,

Capsules

90 caps, 180 caps, 270 caps

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.